Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report
Amivantamab is the first drug approved in EGFR exon 20 insertion-mutated NSCLC. Nevertheless, primary or secondary resistance to amivantamab is a frequent problem in clinical practice. We report a case of a patient with EGFR exon 20-mutated NSCLC who had primary resistance to amivantamab but was suc...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364323001431 |
| _version_ | 1797383661826342912 |
|---|---|
| author | Jaemin Kim, BS Youngjoo Lee, MD, PhD |
| author_facet | Jaemin Kim, BS Youngjoo Lee, MD, PhD |
| author_sort | Jaemin Kim, BS |
| collection | DOAJ |
| description | Amivantamab is the first drug approved in EGFR exon 20 insertion-mutated NSCLC. Nevertheless, primary or secondary resistance to amivantamab is a frequent problem in clinical practice. We report a case of a patient with EGFR exon 20-mutated NSCLC who had primary resistance to amivantamab but was successfully treated by combining therapy of another EGFR exon 20 insertion-specific targeted drug mobocertinib and bevacizumab. |
| first_indexed | 2024-03-08T21:24:18Z |
| format | Article |
| id | doaj.art-7248c4d142d545b5b6b62b07b946ca1d |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-03-08T21:24:18Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-7248c4d142d545b5b6b62b07b946ca1d2023-12-21T07:37:25ZengElsevierJTO Clinical and Research Reports2666-36432023-12-01412100600Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case ReportJaemin Kim, BS0Youngjoo Lee, MD, PhD1Research Institute, National Cancer Center, Goyang, Republic of KoreaResearch Institute, National Cancer Center, Goyang, Republic of Korea; Division of Hematology and Oncology, Department of Internal Medicine, National Cancer Center, Goyang, Republic of Korea; Corresponding author. Address for correspondence: Youngjoo Lee, MD, PhD, Division of Hematology and Oncology, Department of Internal Medicine, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Republic of Korea.Amivantamab is the first drug approved in EGFR exon 20 insertion-mutated NSCLC. Nevertheless, primary or secondary resistance to amivantamab is a frequent problem in clinical practice. We report a case of a patient with EGFR exon 20-mutated NSCLC who had primary resistance to amivantamab but was successfully treated by combining therapy of another EGFR exon 20 insertion-specific targeted drug mobocertinib and bevacizumab.http://www.sciencedirect.com/science/article/pii/S2666364323001431NSCLCEGFR exon 20 insertionDrug resistanceAnti-angiogenesisTargeted therapyCase report |
| spellingShingle | Jaemin Kim, BS Youngjoo Lee, MD, PhD Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report JTO Clinical and Research Reports NSCLC EGFR exon 20 insertion Drug resistance Anti-angiogenesis Targeted therapy Case report |
| title | Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report |
| title_full | Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report |
| title_fullStr | Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report |
| title_full_unstemmed | Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report |
| title_short | Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report |
| title_sort | mobocertinib and bevacizumab for amivantamab refractory lung cancer with egfr exon 20 insertion mutation a case report |
| topic | NSCLC EGFR exon 20 insertion Drug resistance Anti-angiogenesis Targeted therapy Case report |
| url | http://www.sciencedirect.com/science/article/pii/S2666364323001431 |
| work_keys_str_mv | AT jaeminkimbs mobocertinibandbevacizumabforamivantamabrefractorylungcancerwithegfrexon20insertionmutationacasereport AT youngjooleemdphd mobocertinibandbevacizumabforamivantamabrefractorylungcancerwithegfrexon20insertionmutationacasereport |